Nalaganje...

奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制

While treating cancer, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) still faces inevitable drug resistance. Investigations into the mechanisms which foster resistance to EGFR-TKI has led to the discovery of novel biomarkers and drug targets, and in turn has enabled the devel...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Zhongguo Fei Ai Za Zhi
Format: Artigo
Jezik:Inglês
Izdano: 中国肺癌杂志编辑部 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7210090/
https://ncbi.nlm.nih.gov/pubmed/32316715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.02
Oznake: Označite
Brez oznak, prvi označite!